Standout Papers

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused ... 2018 2026 2020 2023 295
  1. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial (2018)
    Simon Portsmouth, David van Veenhuyzen et al. The Lancet Infectious Diseases

Immediate Impact

57 standout
Sub-graph 1 of 21

Citing Papers

Cefepime–Taniborbactam in Complicated Urinary Tract Infection
2024 Standout
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
2024 Standout
3 intermediate papers

Works of Mitsuaki Machida being referenced

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
2018 Standout
Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI)
2017

Author Peers

Author Last Decade Papers Cites
Mitsuaki Machida 209 109 12 271 123 6 405
Tania Mashiach 89 105 28 217 112 11 422
Chi-Chang Huang 90 154 24 200 100 13 399
Nazim Mustafa 132 68 18 310 57 11 442
Yuag-Meng Liu 66 125 24 185 87 8 343
G. Muralidharan 250 92 79 248 57 9 436
Joakim Isendahl 130 82 22 128 73 7 427
Johanna Berkhout 155 124 55 171 36 8 445
Mar Solé 74 70 37 317 74 10 438
Maria C Losada 269 101 20 254 134 13 416
Panagiota Lourida 126 91 53 238 69 14 412

All Works

Loading papers...

Rankless by CCL
2026